Stock data
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE) reported revenue of US$673.00M and net income of -US$575.00M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$673.00M | — | -US$535.00M | -US$575.00M | — |
| 2024 | US$560.00M | — | -US$536.00M | -US$569.00M | — |
| 2023 | US$434.00M | — | -US$569.00M | -US$607.00M | — |
| 2022 | US$363.33M | — | -US$648.92M | -US$707.42M | — |
| 2021 | US$351.41M | — | -US$381.74M | -US$454.02M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$214.00M | -US$92.00M | — |
| 2026-03-31 | US$136.00M | -US$185.00M | — |
| 2025-12-31 | US$207.07M | -US$128.59M | — |
| 2025-09-30 | US$159.93M | -US$180.41M | — |
| 2025-06-30 | US$167.00M | -US$115.00M | — |
| 2025-03-31 | US$139.00M | -US$151.00M | — |
| 2024-12-31 | US$164.65M | -US$133.20M | — |
| 2024-09-30 | US$139.49M | -US$133.52M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.